

ABSTRACT OF THE DISCLOSURE

The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications.

The invention provides methods for enhancing the immune response caused by

5 immunostimulatory oligonucleotide compounds.